Introducing vedolizumab to clinical practice: who, when and how?
Background Vedolizumab (VDZ), a humanized monoclonal antibody that selectively targets alpha4beta7 integrin, is approved for use in inflammatory bowel disease (IBD). Aims To review the evidence for the safety and efficacy of VDZ in IBD, in order to identify patients likely to benefit from therapy an...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2015
|